Prophylaxis and Management of Secondary CNS Lymphoma

Schmitz, 2016, CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34, 3150, 10.1200/JCO.2015.65.6520 Gleeson, 2017, Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial, Annals of oncology : official journal of the European Society for Medical Oncology/ESMO, 28, 2511, 10.1093/annonc/mdx353 Calimeri, 2019, Risk stratification and management algorithms for patients with diffuse large B-cell lymphoma and CNS involvement, Annals of Lymphoma, 3, 7, 10.21037/aol.2019.06.01 Bernstein, 2009, Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516 – the Southwest Oncology Group, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27, 114, 10.1200/JCO.2008.16.8021 Bromberg, 2013, Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation–an International Primary Central Nervous System Lymphoma Study Group project, Haematologica, 98, 808, 10.3324/haematol.2012.070839 Kridel, 2011, Prevention of CNS relapse in diffuse large B-cell lymphoma, The Lancet Oncology, 12, 1258, 10.1016/S1470-2045(11)70140-1 Broder, 1972, Chemotherapy of brain tumors, Prog Exp Tumor Res, 17, 373, 10.1159/000393684 Blasberg, 1975, Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion, J Pharmacol Exp Ther, 195, 73 Abramson, 2010, Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma, Cancer, 116, 4283, 10.1002/cncr.25278 Eyre, 2019, Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity, British journal of haematology, 187, 185, 10.1111/bjh.16070 Puckrin, 2021, Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma, American journal of hematology Wilson, 2020, Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery, Blood Adv, 4, 3586, 10.1182/bloodadvances.2020002421 Orellana-Noia, 2020, CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions, Blood, 136, 27, 10.1182/blood-2020-134798 Cheah, 2014, A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma, British journal of cancer, 111, 1072, 10.1038/bjc.2014.405 McKay, 2020, The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology good practice paper, British journal of haematology, 190, 708, 10.1111/bjh.16866 Roschewski, 2021, Central nervous system prophylaxis in diffuse large B-cell lymphoma: a race to the bottom, Haematologica, 106, 332, 10.3324/haematol.2020.266635 Hegde, 2005, High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology, Blood, 105, 496, 10.1182/blood-2004-05-1982 Masaki, 2011, High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma, Int J Hematol, 93, 720, 10.1007/s12185-011-0848-1 El-Galaly, 2018, Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma, Eur J Cancer, 93, 57, 10.1016/j.ejca.2018.01.073 Patrij, 2011, Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis, Ger Med Sci, 9 Doolittle, 2008, Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report, Blood, 111, 1085, 10.1182/blood-2007-07-101402 Wight, 2019, Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance, British journal of haematology, 187, 174, 10.1111/bjh.16064 Doorduijn, 2017, Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study, Hematol Oncol, 35, 497, 10.1002/hon.2342 Korfel, 2013, Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas, Haematologica, 98, 364, 10.3324/haematol.2012.077917 Ferreri, 2015, High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial, Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 33, 3903, 10.1200/JCO.2015.61.1236 Ferreri, 2021, MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial, Lancet Haematol, 8, e110, 10.1016/S2352-3026(20)30366-5 Swerdlow, 2016, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, 127, 2375, 10.1182/blood-2016-01-643569 Savage, 2016, Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL, Blood, 127, 2182, 10.1182/blood-2015-10-676700 Klanova, 2019, Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL, Blood, 133, 919, 10.1182/blood-2018-07-862862 Schmitz, 2018, Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma, The New England journal of medicine, 378, 1396, 10.1056/NEJMoa1801445 Chapuy, 2018, Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes, Nature medicine, 24, 679, 10.1038/s41591-018-0016-8 Wright, 2020, A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications, Cancer cell, 37, 551, 10.1016/j.ccell.2020.03.015 Isaev, 2021, Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma, Haematologica, 106, 1466, 10.3324/haematol.2020.255950 Ollila, 2021, Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma, Blood, 137, 1120, 10.1182/blood.2020007236 Twa, 2020, Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma (DLBCL), Blood Lionakis, 2017, Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma, Cancer cell, 31, 833, 10.1016/j.ccell.2017.04.012 Grommes, 2017, Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma, Cancer Discov, 7, 1018, 10.1158/2159-8290.CD-17-0613 Simard, 2020, Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma, Blood, 136, 24, 10.1182/blood-2020-137709 Rubenstein, 2018, Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma, Blood Adv, 2, 1595, 10.1182/bloodadvances.2017014845 Frigault, 2019, Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma, Blood, 134, 860, 10.1182/blood.2019001694 Davis, 2010, Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma, Nature, 463, 88, 10.1038/nature08638 Wilson, 2015, Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma, Nature medicine, 21, 922, 10.1038/nm.3884 Grommes, 2019, Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma, Blood, 133, 436, 10.1182/blood-2018-09-875732 Ghesquieres, 2019, Annals of oncology: official journal of the European Society for Medical Oncology/ESMO, 30, 621, 10.1093/annonc/mdz032 Nowakowski, 2019, Addition of Lenalidomide to R-CHOP (R2CHOP) improves outcomes in newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): First report of ECOG-ACRIN1412 A Randomized Phase 2 US Intergroup study of R2CHOP vs R-CHOP, 37, 37 Olszewski, 2020, Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma, Blood, 136, 21, 10.1182/blood-2020-134757 Seoane, 2019, Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases, Annals of oncology: official journal of the European Society for Medical Oncology/ESMO, 30, 211, 10.1093/annonc/mdy544 Khurana, 2021, Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?, Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 39, 1641, 10.1200/JCO.20.01935